Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications.
Interest in producing large quantities of supercoiled plasmid DNA has recently increased as a result of the rapid evolution of gene therapy and DNA vaccines. Owing to the commercial interest in these approaches, the development of production and purification strategies for gene-therapy vectors has been performed in pharmaceutical companies within a confidential environment. Consequently, the information on large-scale plasmid purification is scarce and usually not available to the scientific community. This article reviews downstream operations for the large-scale purification of plasmid DNA, describing their principles and the strategy used to attain a final product that meets specifications.
Ferreira
G N
GN
Centro de Engenharia Biológica e Química, Instituto Superior Técnico, Av. Rovisco Pais, 1049-001 Lisboa, Portugal. gnmferreira@ist.utl.pt
Monteiro
G A
GA
Prazeres
D M
DM
Cabral
J M
JM
D020413:3' Untranslated Regions / Q000302:isolation & purification / Q000378:metabolism*; D000818:Animals; D004278:DNA, Superhelical / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000639:trends; D015316:Genetic Therapy / Q000379:methods* / Q000592:standards / Q000639:trends; D006801:Humans; D010957:Plasmids / Q000138:chemical synthesis* / Q000378:metabolism; D012323:RNA Processing, Post-Transcriptional; D019444:Vaccines, DNA / Q000138:chemical synthesis / Q000235:genetics*
D020413:3' Untranslated Regions; D004278:DNA, Superhelical; D019444:Vaccines, DNA